Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M23-712 Atogepant for Preventive Treatment of Chronic Migraine in Pediatric Subjects
jRCT2031250026Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Atogepant with Placebo (2 arms). Primary endpoints: Number of participants experiencing adverse events and Change from baseline in mean monthly migraine days. Started Apr 2025; status: recruiting.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2031250026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250026.